Alzheimer's drug begins human trials

Jun 27, 2007

Human clinical trials are under way for a U.S. drug to treat Alzheimer's disease, based on the design of a Purdue University researcher.

"Current drugs manage the symptoms, but this could be the first disease-modifying therapy," said Professor Arun Ghosh. "It may be able to prevent and reverse the disease."

Ghosh and Jordan Tang of the Oklahoma Medical Research Foundation developed the drug CTS-21166.

In 2000, Tang identified beta-secretase, a key enzyme in the progression of Alzheimer's that triggers the formation of amyloid plaques in the brain. Ghosh later built a molecule that binds to the enzyme and inhibits its activity.

"These molecules fit together like puzzle pieces," Ghosh said. "We created a molecule that fits with a key piece of the Alzheimer's disease puzzle. When the treatment molecule binds to the enzyme, it changes the shape of that puzzle piece so that it no longer fits in its original spot. This halts the chain reaction that leads to the devastating symptoms of Alzheimer's disease."

Ghosh reports his recent work in the May 17 issue of the Journal of Medicinal Chemistry.

Copyright 2007 by United Press International

Explore further: Most US babies get their vaccines, CDC says

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

Expression of privilege in vaccine refusal

Aug 27, 2014

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

User comments : 0